New York K 1398: Memorializing Governor Kathy Hochul to proclaim the month of May 2026, as Hepatitis B Awareness Month in the State of New York

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
K01398 Summary:

BILL NOK01398 

&nbsp

SAME ASNo Same As

&nbsp

SPONSORRules (Cruz)

&nbsp

COSPNSR

&nbsp

MLTSPNSRButtenschon, Griffin, Santabarbara

&nbsp

&nbsp

Go to top K01398 Actions:

BILL NOK01398 

&nbsp

05/18/2026referred to calendar

05/19/2026adopted

Go to topK01398 Committee&nbspVotes:

Go to topK01398 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topK01398 Text:

Assembly Resolution No. 1398

BY: M. of A. Rules (Cruz)

 MEMORIALIZING Governor Kathy Hochul to proclaim
 the month of May 2026, as Hepatitis B Awareness
 Month in the State of New York

 WHEREAS, Hepatitis B is a liver infection caused by the hepatitis B
virus; current incidence estimates indicate that approximately 1.8
million Americans are infected with hepatitis B virus; and

 WHEREAS, New York has one of the highest hepatitis B burdens in the
nation, with a 2021 study estimating a prevalence of approximately 0.8%,
ranking third among U.S. states; Queens County bears a disproportionate
share of this burden, with an estimated 42,600 residents living with
hepatitis B, the second-highest total among U.S. counties; and

 WHEREAS, Hepatitis B spreads from person to person via contact with
infected blood and/or body fluids; and

 WHEREAS, Hepatitis B infection can range from an acute, mild,
short-term illness to a chronic, serious, long-term infection that can
lead to cirrhosis and liver cancer; and

 WHEREAS, 85% of infants and 50% of older children and adults with
hepatitis B are asymptomatic and about 1 in 2 people who have hepatitis
B are unaware of their infection status; and

 WHEREAS, Infants face an increased hepatitis B exposure risk through
everyday contact and infected family members, and are susceptible to
developing acute and serious health issues if they are infected at birth
or in early childhood; and

 WHEREAS, Infants exposed to hepatitis B have a 90% risk of
developing chronic hepatitis B, greatly increasing their risk of
developing serious liver conditions such as liver cancer or cirrhosis in
their lifetime; and

 WHEREAS, Treatment reduces the risk of serious conditions such as
liver cancer or cirrhosis, but an estimated up to 75 percent of people
who have hepatitis B in the U.S. and are eligible for treatment are not
prescribed treatment, including 40% of those with advanced liver
disease; and

 WHEREAS, To safeguard infant health, in 1991, the Advisory Committee
on Immunization Practices (ACIP) issued its first universal hepatitis B
birth dose recommendation, which led to the implementation of the
universal hepatitis B vaccination program in 1992 in the United States;
and

 WHEREAS, Before the universal hepatitis B birth dose recommendation,
around 18,000 children in the United States were infected each year by
hepatitis B virus before their 10th birthday; and

 WHEREAS, From 1990 to 2019, the universal hepatitis B birth dose
recommendation led to a 99% decline in reported cases of acute hepatitis

B in children and young adults and averted an estimated 90,100 deaths in
the United States: and

 WHEREAS, The ACIP ended this universal hepatitis B birth dose
recommendation in 2025 and now recommends it for infants born to women
who tested positive for the hepatitis B virus or whose status is
unknown, limiting other infants to a recommendation for shared clinical
decision-making; and

 WHEREAS, Public health analyses suggest that skipping or delaying
the hepatitis B birth dose could result in thousands of preventable
hepatitis B infections and hundreds of millions in avoidable healthcare
costs in the United States; and

 WHEREAS, Amidst these changes, several states have reaffirmed their
support for a universal hepatitis B birth dose; and

 WHEREAS, These state level changes are beneficial to the public
health landscape and prosperity of those states; and

 WHEREAS, Given existing shortfalls in annual hepatitis B screening
practices, despite a universal hepatitis B screening recommendation for
pregnant women, vaccination remains the safest and most effective way to
proactively safeguard public health and prevent the devastating effects
of hepatitis B infection; and

 WHEREAS, Given existing gaps related to linkage to care for people
who have hepatitis B, greater awareness of and access to hepatitis B
screening and treatment o